<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02008851</url>
  </required_header>
  <id_info>
    <org_study_id>TNG-CL011</org_study_id>
    <nct_id>NCT02008851</nct_id>
  </id_info>
  <brief_title>A Phase 1, Open-label Safety Study of NKA in Patients With Type 2 Diabetes</brief_title>
  <official_title>A Phase 1, Open-Label Safety and Tolerability Study of an Autologous Neo-Kidney Augment (NKA) in Patients With Type 2 Diabetes and Chronic Kidney Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tengion</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tengion</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if selected renal cells, obtained by biopsy from a&#xD;
      patient with chronic kidney disease (CKD) and Type 2 Diabetes (i.e., autologous cells) can be&#xD;
      safely implanted back into the patient.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1 safety and tolerability study to determine if NKA, manufactured from a&#xD;
      patient's renal biopsy tissue, can be safely implanted back into the kidney of the patient.&#xD;
      Patients must have CKD and Type 2 Diabetes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Lack of funding&#xD;
  </why_stopped>
  <start_date>December 2013</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of adverse events related to study procedures or investigational product</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of renal-specific adverse events</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Changes in renal function over time</measure>
    <time_frame>12 months</time_frame>
    <description>Exploratory objectives include assessment of renal function over time; e.g., glomerular filtration rate (GFR), serum creatinine, and proteinuria.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>Implantation of Neo-kidney Augment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receiving one dose (implant) of NKA into the left kidney</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Neo-kidney augment</intervention_name>
    <description>Injection of 3.0 x 10e6 selected renal cells into the left kidney of the patient</description>
    <arm_group_label>Implantation of Neo-kidney Augment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with type 2 diabetes mellitus (T2DM).&#xD;
&#xD;
          -  Patients with CKD defined as glomerular filtration rate (GFR) of 20 - 50&#xD;
             mL/min/1.73m2, inclusive.&#xD;
&#xD;
          -  Microalbuminuria that cannot be explained by an alternative diagnosis.&#xD;
             Microalbuminuria is defined as a urinary albumin-creatinine ration (UACR) ≥ 30 mg/g or&#xD;
             urine albumin excretion ≥ 30 mg/day on 24 hour urine collection.&#xD;
&#xD;
          -  Ongoing treatment with ACEi or ARB. Patients who are intolerant may be included as&#xD;
             long as they have stable blood pressure.&#xD;
&#xD;
          -  Systolic blood pressure between 105 and 140 mmHg (inclusive) and diastolic blood&#xD;
             pressure ≤ 90 mmHg.&#xD;
&#xD;
          -  The patient should have historical data to provide a reasonable estimate of the rate&#xD;
             of progression of CKD&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Type 1 diabetes mellitus (DM).&#xD;
&#xD;
          -  History of a renal transplant.&#xD;
&#xD;
          -  HbA1c &gt; 10% at Screening.&#xD;
&#xD;
          -  Hemoglobin levels &lt; 9 g/dL prior to biopsy or implant.&#xD;
&#xD;
          -  Known allergy to kanamycin or structurally similar aminoglycoside antibiotics.&#xD;
&#xD;
          -  Abnormal coagulation status as measured by activated partial prothrombin time,&#xD;
             international normalized ratio (INR), and/or platelet count.&#xD;
&#xD;
          -  Ineligible for a biopsy (e.g., based on size or cortical depth), MRI or renal&#xD;
             scintigraphy study (e.g. due to hypersensitivity or allergy) according to standard&#xD;
             site practices.&#xD;
&#xD;
          -  Not a good candidate for laparoscopic surgical procedure (based on the assessment of&#xD;
             the surgeon who will be performing the implant), including patients who are morbidly&#xD;
             obese, have excessive fat surrounding the kidney, have a BMI &gt; 45, or who are&#xD;
             otherwise at excessive risk for serious complications.&#xD;
&#xD;
          -  Clinically significant infection requiring parenteral antibiotics within 6 weeks of&#xD;
             biopsy or implantation.&#xD;
&#xD;
          -  Patients with small kidneys (average size &lt; 9 cm) or only one kidney. Patients with a&#xD;
             rapid decline in renal function over the last 3 months prior to biopsy or acute kidney&#xD;
             injury.&#xD;
&#xD;
          -  Patients with any of the following conditions prior to biopsy: renal tumors,&#xD;
             polycystic kidney disease, renal cysts or other anatomic abnormalities that would&#xD;
             interfere with the biopsy or implantation procedure (e.g., cysts in the pathway of the&#xD;
             injection for implantation), hydronephrosis, skin infection over proposed biopsy&#xD;
             sites, or evidence of a urinary tract infection.&#xD;
&#xD;
          -  Female subjects who are pregnant, lactating (breast feeding) or planning a pregnancy&#xD;
             during the course of the study.&#xD;
&#xD;
          -  History of cancer within the past 3 years (excluding non-melanoma skin cancer and&#xD;
             carcinoma in situ of the cervix).&#xD;
&#xD;
          -  Life expectancy of less than 2 years.&#xD;
&#xD;
          -  Any contraindication or known anaphylactic or severe systemic reaction to either human&#xD;
             blood products or materials of animal (bovine, porcine) origin or anesthetic agents.&#xD;
&#xD;
          -  Positive for Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), or Hepatitis&#xD;
             C Virus (HCV) assessed.&#xD;
&#xD;
          -  Subjects with active tuberculosis (TB) requiring treatment in the past 3 years.&#xD;
&#xD;
          -  Immunocompromised subjects or patients receiving immunosuppressive agents.&#xD;
&#xD;
          -  Subjects with uncontrolled diabetes, incapacitating cardiac and/or pulmonary&#xD;
             disorders.&#xD;
&#xD;
          -  History of active alcohol and/or drug abuse that in the investigator's assessment&#xD;
             would impair the subject's ability to comply with the protocol.&#xD;
&#xD;
          -  Patients with clinically significant hepatic disease.&#xD;
&#xD;
          -  Patients with bleeding disorders that would, in the opinion of the Investigator,&#xD;
             interfere with the performance of study procedures; patients taking Coumarins&#xD;
             (e.g.,Warfarin) or other anticoagulants (e.g. enoxaparin or direct thrombin&#xD;
             inhibitors).&#xD;
&#xD;
          -  Use of any investigational product within 3 months of the biopsy .&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric McAllister, MD, DPhil</last_name>
    <role>Study Director</role>
    <affiliation>Tengion, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Chicago Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LSU Health Care Services</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham &amp; Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UNC Medical Center</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27514</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <study_first_submitted>December 6, 2013</study_first_submitted>
  <study_first_submitted_qc>December 6, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2013</study_first_posted>
  <last_update_submitted>December 10, 2014</last_update_submitted>
  <last_update_submitted_qc>December 10, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 11, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic kidney disease</keyword>
  <keyword>Type 2 Diabetes</keyword>
  <keyword>Neo-kidney augment</keyword>
  <keyword>Regenerative medicine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

